Phaseline

Targets › NY-ESO-1

NY-ESO-1: drug programs, companies and trials

7 programs from 6 companies in 8 trials: 6 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on NY-ESO-1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Takara BioTBI-1301
NY-ESO-1 directed CAR-T cell therapy
NY-ESO-1Phase 3Synovial Sarcomas; NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive PatientsMar 2032
Jonsson Comprehensive Cancer Centerdendritic cell vaccine therapy
NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine
NY-ESO-1Phase 2Malignant NeoplasmNov 2027
M.D. Anderson Cancer CenterNY-ESO-1 TCR/IL-15 NK
NY-ESO-1 T-cell receptor (TCR)-engineered natural killer cells with IL-15 co-expression
NY-ESO-1, IL15Phase 1Synovial SarcomaNov 2026
Guangzhou FineImmune BiotechnologySuper1 TCR-T
T-cell receptor engineered T cell targeting NY-ESO-1
NY-ESO-1Phase 1SarcomaApr 2027
TCRCure BiopharmaTC-N201 cells
T cells genetically engineered with a TCR targeting NY-ESO-1
NY-ESO-1Phase 1Advanced Solid TumorsNov 2027
M.D. Anderson Cancer CenterAllogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer
Cord blood-derived NK cells transduced with NY-ESO-1 T-cell receptor and IL-15
NY-ESO-1, IL15Phase 1Relapsed/Refractory MyelomaAug 2028
Roswell Park Cancer InstituteGenetically Engineered NY-ESO-1-specific T Lymphocytes
Genetically engineered T cells targeting NY-ESO-1 tumor-associated antigen
NY-ESO-1Phase 1Recurrent Fallopian Tube CarcinomaMar 2032

Conditions

Synovial Sarcomas (1) NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients (1) Relapsed/Refractory Myeloma (1) Advanced Solid Tumors (1) Sarcoma (1) Recurrent Fallopian Tube Carcinoma (1) Malignant Neoplasm (1) Synovial Sarcoma (1)

Modalities

mixed (5), protein or peptide (1), small molecule (1)

Companies

M.D. Anderson Cancer Center (2) Takara Bio (1) TCRCure Biopharma (1) Guangzhou FineImmune Biotechnology (1) Roswell Park Cancer Institute (1) Jonsson Comprehensive Cancer Center (1)

Related targets

IL15 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.